FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the financial year ended May 31, 2003
Lorus Therapeutics Inc.
-----------------------
(Translation of registrant's name into English)
2 Meridian Road, Toronto, Ontario M9W 4Z7
-----------------------------------------
(Address of principal executive offices)
[Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F.]
Form 20-F Form 40-F X
-------- --------
[Indicate by check mark whether the registrant by
furnishing the information contained in this Form is also
thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
-------- --------
[If "Yes" is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-
--------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Lorus Therapeutics Inc.
Date: January 29, 2004 By: "Shane Ellis"
---------------- ----------------
Shane Ellis
Vice President, Legal Affairs
Corporate Secretary